Fluzone High-Dose (inactivated influenza virus vaccine, from Sanofi Pasteur) has been approved for use in adults ages 65 years and older to prevent disease caused by influenza virus subtypes A and B. People in this age group are at highest risk for seasonal influenza complications, which may result in hospitalization and death. Fluzone High-Dose was approved via the accelerated approval pathway. In clinical studies, Fluzone High-Dose demonstrated an enhanced immune response compared with Fluzone in individuals 65 and older.
Fluzone High-Dose is administered as a single injection in the upper arm and is available in single dose pre-filled syringes without preservative.
For more information call (800) VACCINE or visit www.sanofipasteur.us.